secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001683168-24-005697
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial
--------------------------------------------------------------------------------

- Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.
- Cash balance $9.1M as of June 30, 2024.
- Ethics approvals granted for Hemopurifier safety study in solid tumor patients on anti-PD-1 therapy.
- Expects to open patient enrollment in October 2024; additional sites anticipated by end of 2024.
- COVID-19 trial in India remains open; one patient treated to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/0001683168-24-005697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer